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The eyes are exposed to oxidative stress due to light absorption and the high metabolism rate of their
tissue cells. Oxidative stress plays an important role in the pathogenesis of many major eye diseases,
including ocular inﬂammation, neovascularization, age-related macular degeneration, glaucoma, and
cataracts. Herbal molecules, such as lutein, zeaxanthin, omega-3 fatty acids, vitamin C, and vitamin E,
have been tried as ocular aliments. Although there are many positive outcomes for preventive or even
therapeutic uses for ocular diseases, the efﬁcacy remains controversial. Nevertheless, traditional Chinese
medicine remains the best choice of herbal molecules mining for ocular remedies.
Copyright  2014, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Many herbal remedies have been applied for eye ailments for a
long time, as recorded in different ancient and modern Chinese
Pharmacopoeia. They can be used for treatment of night blindness,
cataract, ﬂoaters, and glaucoma. The efﬁcacy of these remedies is
based on experiences and discrete clinical outcomes, without
strictly passing through modern systematic scientiﬁc assessments
including animal testing and clinical trials. Furthermore, the efﬁ-
cacies have also been reputed as having a large variation due to
nonstandardized sources, qualities, combinations, and preparation
methods of herbal remedies. Nevertheless, these long-documented
historical remedies are a goldmine for natural products discovery.
In order to overcome the problems of variations, deﬁned herbal
extracts and herbal molecules provide a better option for future
development.
The eye is a high metabolism organ and suffers from consistent
photooxidation by light. The tissue cells of the eye are susceptible to
oxidative damage.1 Although there are many pathological factors
associated with ocular diseases such as age, genetic predisposition,
oxidation stress, inﬂammation, tumorigenesis, angiogenesis,ave no conﬂicts of interest.
logy and Visual Sciences, The
Hospital, 147K, Argyle Street,
ciety of Taiwan. Published by Elseischemia, and diabetes, oxidative stress seems to play a key role in
the pathogenesis of ocular diseases.1e3
Several risk factors have been attributed to age-related macular
diseases (AMD) such as aging,4 cigarette smoking,5 sunlight expo-
sure, high fat, low antioxidant intake,6 and genetic variants (e.g.,
polymorphism of complement factor H).7 All these risk factors are
correlated with oxidative stress resulting in retinal tissue damage,
including damage to photoreceptor cells, retinal pigment epithe-
lium, and choroidal capillaries.
Glaucoma causes progressive, irreversible loss of retinal gan-
glion cells, damage of the optic nerve, and loss of vision with and
without increased intraocular pressure. Oxidative stress causes
cytotoxic effects, retinal ganglion cell death,8 and trabecular
meshwork damage which leads to obstruction of aqueous humor
outﬂow, resulting in intraocular pressure elevation.9
Cataract is caused by opacity of the lens as a result of long-term
light exposure. This photooxidation decomposes biological com-
ponents of the lens,10 mainly crystallin. Oxidized thiol groups of
crystalline molecules form disulﬁde bonds, which subsequently
lead to crystalline aggregation and cataract formation.11
Diabetes causes oxidative stress increase to induce capillary
cells and retinal microvasculature damages. Glyceraldehyde-3-
phosphate dehydrogenase impairment in diabetes also causes
improper activation of major biochemical pathways, leading to the
pathogenesis of diabetic retinopathy.12,13
Graves’ ophthalmopathy (GO) is characterized by protrusion of
the eye ball, partly caused by hyperthyroidism. It affects 25e50%
Graves’ patients. About 5% GO patients have a potential sightvier Taiwan LLC. All rights reserved.
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involvement in the pathogenesis of GO.15e17 Overproduction of
thyroid hormones accelerates the basic metabolic rates and cellular
oxidative metabolism in mitochondria resulting in reactive oxygen
species (ROS) overproduction. This oxidative environment can
subsequently stimulate retroocular ﬁbroblasts cell proliferation18
leading to eye protrusion. The mechanism was supported by
some ﬁndings that a higher 8-hydroxy-20-deoxyguanoin (8-OHdG)
level was found in urine of active GO patients (CAS > 3) and higher
levels of 8-OHdG, malondialdehyde (MDA), superoxide anions, and
hydrogen peroxides in GO orbital ﬁbroblasts.3
Because oxidative stress plays an important role in the patho-
genesis of these common eye diseases, many studies showed that
herbal remedies possess various antioxidants which has potential
use for eye protection. Many studies have investigated if the ther-
apeutic or preventive effects of herbal molecules in cells, animal
models, and clinical trials are related to antioxidation effects.19,20
2. Lutein and zeaxanthin
Lutein and zeaxanthin belong to the xanthophyll family of ca-
rotenoids commonly found in tomatoes, Chinese wolfberry fruit,
and carrots. They are isomers with a double bond difference (Fig. 1).
Lutein has three chiral centers whereas zeaxanthin has two.21 The
(3R,30S) and (3S,30R) stereoisomers of zeaxanthin are symmetrical
and identical. Therefore, zeaxanthin has only three stereoisomeric
forms. The principal natural form of zeaxanthin is (3R,30R)-
zeaxanthin.22
Pyridinium bisretinoid products, A2-PE and A2E, are the
byproducts derived from all-trans-retinal in the visual cycle
(Fig. 2).23 Photooxidation of ARPE-19 is protected by zeaxanthin,
which is more potent than alpha-tocopherol. Zeaxanthin can be
potentiated by combining with alpha-tocopherol.24 In this case,
zeaxanthin acts as a photo ﬁlter, absorbing photons so as to inhibit
ROS and 5a-tocopherol-OOH generation. Ascorbic acid or alpha-
tocopherol acts as antioxidant to regenerate zeaxanthin.
The number of apoptotic rods and cones inversely correlated
signiﬁcantly with zeaxanthin and lutein concentration in the retina
in a light-damaged quail eye, demonstrating that retinal zeaxanthin
protects photoreceptors from light-induced damage.25,26 Zeax-
anthin supplementation inhibited lipid peroxide, protecting DNA,
electron transport complex III, nitrotyrosine, and mitochondrial
superoxide dismutase from damage in diabetic rats.27 It alsoFig. 1. Structure of (A) luprevented vascular endothelial growth factor and intercellular
adhesion molecule-1 expression from increasing in retinas of dia-
betic patients.27 Lutein also protects retina from diabetes-induced
oxidative stressed.28 Choroidal neovascularization in mice was
signiﬁcantly suppressed following 3 days of oral lutein pretreat-
ment, in comparison with vehicle, in a laser-induced choroidal
neovascularization animal model. Macrophage inﬁltration into the
choroidal neovascular membrane, inﬂammation-related molecules
expression including vascular endothelial growth factor, monocyte
chemotactic protein-1, intercellular adhesionmolecule-1, and IkB-a
degradation, and NF-kB p65 translocation were suppressed.29
Lutein and zeaxanthin consumption was also found to be
associated with a lower risk of AMD30 in the Age Related Eye Dis-
eases Study. Dietary lutein or zeaxanthin can reduce the risk of age-
related macular degeneration, geographic atrophy, and large or
extensive intermediate drusen, with odds ratios ¼ 0.65, 0.45, and
0.73, respectively.31 However, they were found to be positively
associated with AMD progress (odds ratio ¼ 2.65, 95% conﬁdence
interval ¼ 1.13e6.22)32 in a prospective study with 7 years follow
up. Therefore, the clinical effects of lutein or zeaxanthin in age-
related macular degeneration are controversial.
3. Omega-3 fatty acids
Omega-3 fatty acids are long-chain polyunsaturated fatty acids
that have a common ﬁnal carbon-carbon double bond between the
last third and fourth carbon of the fatty acid chain (Fig. 3). They are
essential fatty acids, which mean essential for health maintenance.
However, they must be obtained from diet, because the body
cannot synthesize them. Common sources from plants include algal
oil, ﬂaxseed oil, and sea buckhorn seed.33 Docosahexaenoic acid
(DHA), all-cis-docosa-4,7,10,13,16,19-hexaenoic acid [22:6(n-3)],
has 22 carbons with six conjugated double bonds. Eicosapentae-
noic acid (EPA), (5z, 8z, 11z, 14z, 17z)-eicosa-5,8,11,14,17-pentenoic
acid [20:5 (n-3)], has 20 carbons and ﬁve conjugated double
bonds. These omega-3 fatty acids are extensively studied in ocular
health maintenance. DHA is the major fatty acid constituted in the
outer segment disc membrane of retinal photoreceptors. The bio-
physical and biochemical properties of DHA can affect the integrity
and function of the membrane through altering the permeability,
ﬂuidity, thickness, lipid phase properties, and activation of
membrane-bound proteins, which subsequently affect the photo-
transduction and vision.34tein; (B) zeaxanthin.
Fig. 2. Visual cycle and A2E formation. A2E is formed from all-trans-retinal when it reacts with phosphatidylethanolamine in the visual cycle in the photoreceptor outer segments.
Precursor A2-PE is formed. After a multi-step biological process, A2E is released following phosphate hydrolysis [23].
OH O O
OH
H
OH
O
-
H
+
H
+
. OH O O
OH
H
OH
O
Fig. 4. Oxidation of ascorbic acid.
CH3 CH3
OH
K.-O. Chu, C.-P. Pang / Taiwan Journal of Ophthalmology 4 (2014) 103e109 105Omega-3 fatty acids also act as antioxidants. Their poly-
unsaturated conjugated bonds provide a sink to absorb electrons
from reactive species. They remove electrons from free radicals
through formation of peroxides, to protect cell membranes and
other macromolecules from attack. It has been reported that
omega-3 fatty acids prevented free radical-induced hemolysis,35
abnormal in vitro low-density lipoprotein oxidation,36 excessive
superoxide anion generation,37,38 and oxidative stress within
platelets.39
In addition, DHA also reduced caspase-3 expression and
genomic DNA fragmentation in serum-starved PC-12 and Neuro-2A
cells, thereby inhibiting the apoptosis of neuronal cells.40 DHA
inhibited photoreceptor cell apoptosis, prolonged its survival
in vitro,41 and promoted differentiation of developing photorecep-
tors.42 DHA treatment reduced Bax and increased bcl-2 expression,
protected mitochondrial membrane structure, and preserved
photoreceptors from apoptosis when the rat photoreceptors were
exposed to paraquat in vitro.43
Several epidemiology studies examined the relationship be-
tween omega-3 fatty acids or ﬁsh intake with prevalence of age-
related macular degeneration. A systematic review with 88,974
people showed the amount of omega-3 fatty acids or ﬁsh con-
sumption largely associated with decreased risk of age-related
macular degeneration.6 Increased omega-3 fatty acids consump-
tion correlated with decreased occurrence of late age-related
macular degeneration development, with an odds ratio of 0.62
and 95% conﬁdence interval 0.48e0.82. Consumption of ﬁsh more
than twice a week was also associated with a decreased risk of
occurrence of both early age-related macular degeneration (odds
ratio ¼ 0.76) and late age-related macular degeneration (odds
ratio ¼ 0.67).6 However, no randomized, control trials were re-
ported and further investigation is needed to conﬁrm the results.
Another controlled clinical study demonstrated that omega-3 fatty
acids have a beneﬁcial on diabetic retinopathy.44 However, theO
OH CH31
α
9 12 15 18
ω1369
Fig. 3. Structure of omega-3 fatty acid.study was limited by a small sample size. Also, no outcome of the
progress of diabetic maculopathy has been mentioned.
4. Vitamins C and E
Vitamin C (L-ascorbic acid) is a six-carbon lactone that is syn-
thesized from glucose in the livers of most mammalian species, but
not in humans and some primates who lack an enzyme, gulono-
lactone oxidase, which is essential for the synthesis of vitamin C.45
It is commonly available in citric fruits. Vitamin E is a family of
alpha-, beta-, gamma-, and delta-tocopherols corresponding to four
tocotrienols. Of these, alpha-tocopherol is the most extensively
studied vitamin E, because it has the highest bioavailability and is
the only form of vitamin E required by humans.46 It is found in
wheat germ oil, sunﬂowers, and safﬂower oil.
Ascorbic acid donates two electrons from a double bond be-
tween the second and the third carbon, to prevent the other
compound from oxidation (Fig. 4).42 Vitamin E (Fig. 5) can protect
cell membranes from lipid peroxidation by scavenging ROS andO
CH3
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Fig. 5. Structure of a-tocopherol.
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bility, vitamin E is located in the interface between the cell mem-
brane and the extracellular matrix space, facilitating membrane
protection. Vitamin C and vitamin E may form a recycling circuit.
The oxidized form of vitamin E, i.e., tocotrienoxyl or tocopheroxyl
radical can be regenerated to the reduced native state, tocotrienol
and tocopherol, through oxidation of vitamin C and glutathione
(Fig. 6).48,49
The National Health and Nutrition Examination Survey II study
reported the amount of ascorbic acid consumption and its serum
levels were inversely associated with the number of cataract
cases.46,50 Supporting51,52 and conﬂicting results53e55 were also
reported. Similarly, conﬂicting results were also found in vitamin E.
A lower prevalence of cataracts was found in individuals with high
vitamin E intake compared to controls,56,57 but no association was
reported.51,58 Linxian studies found that individuals with multivi-
tamins or mineral supplementation had a signiﬁcant reduction of
nuclear cataract prevalence by 43% compared to controls.59 In
addition, the REACT Study showed that antioxidants given (vitamin
C 750 mg; vitamin E 600 IU, and beta-carotene, 18 mg) daily for 3
years have a small but signiﬁcant positive effect.60 However, the
VECAT Study found that a supplement of 500 mg vitamin E daily
over 4 years showed no clinically signiﬁcant effect on the number of
incidences and progression of nuclear or cortical cataracts.61 The
AREDS Trial randomly gave 4629 participants oral antioxidants
(vitamin C, 500 mg; vitamin E, 400 IU; and beta carotene, 15 mg) or
placebo daily; after an average of 6.3 years follow up, no statistically
signiﬁcant effect was found on the development or progression of
age-related lens opacities (odds ratio ¼ 0.97, p ¼ 0.55).62 Therefore,
the antioxidative effects of vitamins on cataracts remain to be
further investigated.
The association of age-related macular degeneration and anti-
oxidative vitamins was also investigated. A higher dosage of oral
vitamin C supplement, or a higher plasma level of vitamin C was
associated with a lower incidence of AMD, but the results are not
signiﬁcant,63,64 or even without protection.65 Although serum
levels of vitamin E in age-related macular degeneration patients
were lower than those in age-matched controls,60,66 no protective
effect of vitamin E supplementation was found.60,67 None of theFig. 7. Structure of isoliquiritigenin.vitamin C or E supplements showed prevention of early onset of
age-related macular degeneration in three randomized, controlled
trials.68
The Age-Related Eye Disease Study investigated antioxidant
(beta-carotene, vitamin C, vitamin E, and zinc) supplement effects
on the progression of advanced age-related maculopathy, showing
an odds ratio of 0.68 with 99% conﬁdence intervals of 0.49e0.93.
People taking supplements were less likely to lose 15 or more let-
ters of visual acuity.69 Based on this evidence, antioxidants may
protect age-related macular degeneration from progression but not
onset.
5. Herbal molecules in our study
Four herbal chemicals, isoliquiritigenin (ISL) (Fig. 7) from lico-
rice, epigallocatechin gallate (EGCG) (Fig. 8) from green tea,
resveratrol (Fig. 9) from grapes, and gambogic acid (Fig. 10) from
the resin of Garcinia hanburyi, were screened on human umbilical
vein endothelial cells to assess their effects on cell growth and
migration. ISL, EGCG, and resveratrol at sub-cytotoxic levels (10, 50,
and 10 mM, respectively), suppressed vascular endothelial growth
factor-induced endothelial cells proliferation and migration,
whereas gambogic acid showed toxicity even at nanomolar
levels.70 The inhibition on endothelial cell migration by ISL and
EGCG are even higher than that by bevacizumab, a humanized
monoclonal antibody against vascular endothelial growth factor.
Western blot analysis showed that these chemicals affected local
adhesion kinase activation and pigment epithelial growth factor
expression. Therefore, ISL, EGCG, and resveratrol could be potential
candidates to treat ocular diseases with neovascularization, such as
exudative age-related macular degeneration and proliferative dia-
betic retinopathy.70
ISL was further investigated for its anti-angiogenesis effect,
because it appears as the most potent compound amongst them. ItFig. 8. Structure of epigallocatechin gallate.
Fig. 9. Structure of resveratrol.
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in an ex ovo chick chorioallantoic membrane (CAM) assay. It also
suppressed silver nitrate-induced corneal neovascularization with
5 mM topical application. Western blot showed that it suppressed
VEGF, but upregulated PEDF expression at 10 mM in cell culture.71
Catechins, the active constituents of green tea, are reputed for
their antioxidative, anti-inﬂammatory, and anti-angiogenic activ-
ities. We investigated the pharmacokinetics and in vivo effect on
oxidation status of catechins in rat eyes after oral administration.
Gallocatechinwas dominant in the retina, and epigallocatechinwas
dominant in aqueous humor. Signiﬁcant reductions in 8-epi-iso-
prostane levels were found in different tissue compartments, but
not the choroid-sclera or plasma, indicating that catechins exerted
antioxidative activities in these tissues and suggesting that these
compounds could be used as potential drugs for oxidative ocular
diseases associated with oxidative stress.72 In addition, many other
studies showed that catechins can protect nerves in retina
following ischemia/reperfusion insult.73 Catechins are nontoxic
compounds, even for the fetus, although EGCG showed weak
embryotoxicity. Therefore, they can be safely applied at high doses
for long-term use.
We also showed that catechins and green tea extract can sup-
press sodium iodate-induced oxidative retinal degeneration.
Through direct free radical neutralization, anti-oxidative enzymes,
glutathione peroxidase and superoxide dismutase, and apoptosis
molecule, caspase 3, induction by the stress was prevented. His-
tology and fundus photography demonstrated that the retinal
damage was protected after green tea extract administration 21
days after the oxidative insult. Green tea extract also protected
endotoxin-induced ocular inﬂammation. The inﬂammation
markers, monocyte chemoattractant protein-1, protein, tumor ne-
crosis factor-alpha (TNF-a), and interleukin-6 concentration in the
aqueous humor were signiﬁcantly suppressed. Histology showed
that immune cells inﬁltration in the anterior chamber is greatly
reduced. The clinical features of inﬂammation in the anterior
chamber were suppressed after green tea extract administration.
We found that topical application of 5 mg Ginkgo biloba extract
on corneas four times daily suppressed dexamethasone-induced
intraocular pressure elevation and reduced the accumulation of
extracellular materials within the cribriform layers of the trabec-
ular meshwork associated with dexamethasone. In cultured humanO O
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Fig. 10. Structure of gambogic acid.trabecular meshwork cells, Ginkgo biloba extract substantially
reduced anti-Fas ligand-induced apoptosis and reduced
dexamethasone-induced myocilin expression. It also modulated
the expression of stress-related genes, alpha B-crystallin, and heat
shock proteins 70 and 90 alpha. Furthermore, pathological changes
associated with dexamethasonewere found to be smaller in Ginkgo
biloba extract-treated or primed trabecular meshwork cells.74
Ginkgo biloba extract may be another choice for glaucoma
treatment.6. Nicotinamide
Nicotinamide is commonly found in red rice. Allopurinol and
nicotinamide were given at a dose of 300 mg daily for 3 months, as
oral antioxidants, for GO treatment. Eighty-two percent of GO pa-
tients showed improvement with these antioxidants compared to
27% of GO patients given placebo.62 This is supported by Hiromatsu,
who showed that nicotinamide could inhibit orbital ﬁbroblasts
activation induced by interferon-g or TNF-a, because it could
remove ROS that induced glycosaminoglycans accumulation by
retroocular ﬁbroblasts.757. Perspectives
Following the improvement of our understanding on the path-
ogenesis of ocular diseases, we conclude that oxidative stress plays
an important role in these diseases. However, the therapeutic ef-
fects of antioxidation of herbal molecules remain controversial. In
fact, herbal molecules can interact with regulatory molecules in
many pathways to modulate various biological effects.76 They also
modulate gene expressions through epigenetic alteration, by direct
molecular interaction, or change of redox status.77 Complicated
pharmacodynamics and pharmacokinetics interactions of herbal
molecules in conjunction with non-standardized herbal prepara-
tions and medical practice cause a large variation in therapeutic
results. Recently, an exhaustive herbalome project has launched.78
It tries to isolate, identify, and characterize herbal preparations into
deﬁned mixtures or even molecules. Dehydrocorybulbine is an
example molecule being isolated and identiﬁed as a novel analgesic
from Corydalis yanhusuo under this project.79 With such huge
project investment on herbal molecule mining, the therapeutic use
of herbal molecules on ocular treatment could become realistic in
the near future.References
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